Articles

Crispr Chronicles: Pioneering Gene Editing in Cardiovascular Therapy

/in /by

CRISPR-Cas systems have revolutionized gene editing, offering precise and efficient genome modifications with vast applications in biomedical research and therapeutic interventions. This technology has surpassed traditional methods such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) due to its simplicity, cost-effectiveness, and high accuracy. In cardiovascular disease (CVD) research, CRISPR has been instrumental in generating precise disease models, identifying genetic risk factors, and developing potential therapeutic strategies. Genome editing has enabled the correction of monogenic mutations linked to inherited cardiomyopathies and arrhythmias while also targeting metabolic risk factors such as PCSK9 to reduce atherosclerosis.

Advancements such as base editing, prime editing, and RNA editing have further enhanced CRISPR’s precision, minimizing off-target effects and improving therapeutic applicability. Delivery methods, including adeno-associated viral (AAV) vectors and nanoparticle-based strategies, have been optimized to enhance efficiency and safety. Despite these breakthroughs, challenges such as unintended genetic modifications, immune responses, and ethical concerns regarding germline editing persist. The successful clinical translation of CRISPR therapies will require further refinement, rigorous validation, and regulatory oversight to ensure safety and efficacy.

As research continues to advance, CRISPR-based genome editing holds immense promise for transforming cardiovascular medicine. Future developments in delivery technologies, improved gene-editing accuracy, and ethical considerations will play a crucial role in integrating CRISPR into clinical practice. With continued innovation, CRISPR has the potential to become a groundbreaking therapeutic tool, offering precise and long-lasting solutions for cardiovascular diseases and other genetic disorders.

Artificial Intelligence-Driven Advances in Haemophilia Gene Therapy

/in /by

Hemophilia is the most frequent severe genetic haemorrhagic condition. Hemophilia A and B are caused by a lack or dysfunction of the factor VIII and factor IX proteins, respectively, and are distinguished by prolonged and heavy bleeding after minor trauma or even spontaneously. Treatments for hemophilia have been extremely expensive and required the infusion of plasma clotting factors throughout one’s life. The last few years have brought major breakthroughs in gene therapy that now hold real promise for possible curative options. Artificial intelligence has the potential to transform all levels of hemophilia gene therapy, from vector design to predictive modeling and biomarker identification. This review highlights selected applications of AI towards precision medicine including viral vector design, predictive modeling for gene editing, and deep phenotyping in hemophilia gene therapy. It can greatly improve the efficacy and safety of gene therapy through off-target effects prediction, optimization designs of delivery vectors, and determination of personalized combinations of treatments. Consequently, this will also enable accelerated biomarker development for disease diagnosis and monitoring. In such a way, artificial intelligence in hemophilia gene therapy will revolutionize the framework of treatment and make it personalized or even curative for patients all over the world.